AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically ...

Key Points Regeneron Pharmaceuticals is acquiring 23andMe for $256 million. Regeneron is going to keep the consumer genetics business. A big opportunity lies in using much of that data for research ...

Intellia Therapeutics (NTLA) stock drops on safety concern in a Phase 3 trial for gene editing therapy nex-z developed with ...

Regeneron Pharmaceuticals Inc. closed 50.02% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Intellia Therapeutics shares fell 25% amid safety concerns in Phase 3 trials. Check out if today's selloff in NTLA stock is a ...

In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...

A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its incidence has been gradually increasing over the past 30 to 40 years. The ...

Major indices traded higher on Thursday as market participants digested news that while a federal court struck down Donald ...

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, technological advancements, widespread smartphone usage, ...